News
OMER
--
0.00%
--
Omeros Corporation to Announce First Quarter Financial Results on May 10, 2021
Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its first quarter financial results for the period ended March 31, 2021, on Monday, May 10, 2021, after the market closes. Omeros management will host a conference call and webc...
BusinessWire · 12h ago
Omeros (NASDAQ:OMER) Shareholders Have Enjoyed A 42% Share Price Gain
While Omeros Corporation ( NASDAQ:OMER ) shareholders are probably generally happy, the stock hasn't had particularly...
Simply Wall St. · 1d ago
CDC and CMS OKs Omeros' ICD-10 codes for HSCT-TMA diagnosis and narsoplimab
Omeros (OMER) announces that the Centers for Disease Control and Prevention ((CDC)) has approved an International Classification of Diseases (ICD-10) diagnosis code, M31.11 – hematopoietic stem cell transplantation-associated thrombotic microangiopathy
Seekingalpha · 1d ago
Omeros Corporation Announces Approval of ICD-10 Codes for HSCT-TMA Diagnosis and for Narsoplimab Administration
Omeros Corporation (Nasdaq: OMER) today announced that the Centers for Disease Control and Prevention (CDC) has approved an International Classification of Diseases (ICD-10) diagnosis code, M31.11 - hematopoietic stem cell transplantation-associated thromb...
BusinessWire · 1d ago
DJ Omeros Price Target Cut to $32.00/Share From $34.00 by HC Wainwright & Co.
Dow Jones · 04/26 10:46
DJ Omeros Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 04/26 10:46
HC Wainwright Adjusts Omeros' Price Target to $32 From $34, Keeps Buy Rating
MT Newswires · 04/26 08:06
Purpura Therapy Drugs Market Latest Research On Industry Growth, Trends, Top Players, & Key Regions By 2027
Apr 23, 2021 (Market Insight Reports) -- The latest report as Purpura Therapy Drugs Market acknowledges Size, Application Segment, Type, Regional Outlook,...
Market Insight Reports · 04/23 20:21
Ketorolac Tromethamine Market Size 2021 : Top Manufacturers, Industry Share, Regional Analysis, Types and Applications and Forecasts to 2027
Apr 23, 2021 (Market Stats News via COMTEX) -- The latest report as Ketorolac Tromethamine Market acknowledges Size, Application Segment, Type, Regional...
Market Stats News · 04/23 08:10
Complement 3 Glomerulopathy (C3G) Treatment Market is Expected to Witness Rapid Growth by 2030 | Alexion Pharmaceuticals Inc., Omeros Corporation, Apellis Pharmaceuticals, Novartis International AG.
Apr 22, 2021 (MARKITWIRED via COMTEX) -- The complement 3 glomerulopathy (C3G) is a group of rare kidney disorders driven by dysregulation of the complement...
Markitwired · 04/22 12:56
Epstein-Barr Virus (HHV-4) Infections Treatment Market 2021 by Key Players, Regions, Type and Application, Forecast to 2031
Apr 22, 2021 (WiredRelease via Comtex) -- The latest research report provides a complete assessment of the Global Epstein-Barr Virus (HHV-4) Infections...
marketresearch.biz · 04/22 06:47
Global Plasminogen Market 2021 Key Drivers and Challenges, Opportunities and Forecast Insights by 2026
Apr 21, 2021 (CDN Newswire via Comtex) -- MarketsandResearch.biz has announced the addition of a new report entitled Global Plasminogen Market Growth...
CDN Newswire · 04/21 17:00
Bipolar Disorder Therapeutics Industry Size 2021 Research Report by Market Scope, Market Segmentation, Research Method, Competition Analysis and Forecast to 2026
Apr 21, 2021 (The Expresswire) -- Final Report will add the analysis of the impact of COVID-19 on this industry. “Bipolar Disorder Therapeutics Market”...
The Express Wire · 04/21 10:56
Global Obsessive-Compulsive Disorder Treatment Market Insights, Overview, Analysis and Forecast 2021-2026
Apr 20, 2021 (Heraldkeepers) -- The Obsessive-Compulsive Disorder Treatment market report provides a detailed analysis of global market size, regional and...
Heraldkeepers · 04/20 08:25
Global Binge Eating Disorder Treatment Industry Market Insights, Overview, Analysis and Forecast 2021-2027
Heraldkeepers · 04/20 07:17
Global Gastrointestinal Stromal Tumor (GIST) Drug Market Outlook, Industry Analysis and Prospect 2021-2026
Apr 15, 2021 (Heraldkeepers) -- The Gastrointestinal Stromal Tumor (GIST) Drug market report provides a detailed analysis of global market size, regional and...
Heraldkeepers · 04/15 15:04
Global Epstein-Barr Virus (HHV-4) Infections Treatment Market Outlook, Industry Analysis and Prospect 2021-2026
Heraldkeepers · 04/15 15:02
Global Atypical Hemolytic Uremic Syndrome Drug Market Outlook, Industry Analysis and Prospect 2021-2026
Apr 15, 2021 (Heraldkeepers) -- The Atypical Hemolytic Uremic Syndrome Drug market report provides a detailed analysis of global market size, regional and...
Heraldkeepers · 04/15 15:02
Memory Impairment Treatment Market Size Analysis by Competitive Landscape 2021 Latest Research by Top Key Players, Global Share with SWOT Analysis, and Growth Analysis with Revenue till 2027
Apr 14, 2021 (The Expresswire) -- "Final Report will add the analysis of the impact of COVID-19 on this industry." Global “Memory Impairment Treatment...
The Express Wire · 04/14 09:13
Atypical Hemolytic Uremic Syndrome Drug Market Research Report by Type, by Product, by Application - Global Forecast to 2027 - Cumulative Impact of COVID-19
Apr 06, 2021 (Market Insight Reports) -- CANADA - QYResearchMedical recently added a research report, Atypical Hemolytic Uremic Syndrome Drug market – global...
Market Insight Reports · 04/06 19:32
Webull provides a variety of real-time OMER stock news. You can receive the latest news about Omeros through multiple platforms. This information may help you make smarter investment decisions.
About OMER
Omeros Corporation is a commercial-stage biopharmaceutical company. The Company is engaged in discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, complement-mediated diseases and disorders of the central nervous system. The Company’s drug product OMIDRIA (phenylephrine and ketorolac intraocular solution) is used during cataract surgery or intraocular lens (IOL) replacement. The Company’s clinical-stage development programs are focused on complement-associated thrombotic microangiopathies, complement-mediated glomerulonephropathies, Huntington’s disease and cognitive impairment, and addictive and compulsive disorders. It also offers a diverse group of preclinical programs and platforms that are used to unlock new G protein-coupled receptor (GPCR) drug targets and to generate antibodies.